文献出处:JAMA Neurol. 2019 Sep 16. doi: 10.1001/jamaneurol.2019.2984. [Epub ahead of print]Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial.
(hazard ratio, 3.20 [95% CI, 1.44-7.13]) compared with shorter durations of clopidogrel (P for trend=0.06).Conclusions:In the VOYAGER PAD trial, rivaroxaban plus aspirin reduced the risk of adverse cardiovascular and limb events with an early benefit for acute limb ischemia regardless of ...
A combined antithrombotic regimen ofrivaroxabanplusaspirinwas safe and effective for reducing ischemic events in patients with symptomaticperipheral artery diseasewho had just undergone peripheral artery revascularization in VOYAGER PAD, a multicenter randomized trial with nearly 6,600 patients. The study and...
This prospective randomized controlled trial was conducted to provide guidance for clinical medication practices by comparing the efficacy and safety of aspirin and rivaroxaban for prevention of post-TKA venous thrombosis. SUBJECTS AND METHODS Design A prospective, randomized, double-blind, ...
XARELTO®, in combination with aspirin, is indicated to reduce the risk of major cardiovascular events (cardiovascular death, myocardial infarction, and stroke) in adult patients with coronary artery disease (CAD). XARELTO®, in combination with aspirin, is indicated to reduce the risk of major...
they are at high risk for major adverse limb events, and new findings from a prespecified analysis of data from the VOYAGER-PAD trial show that treatment with the direct-acting oral anticoagulant rivaroxaban along with aspirin significantly cut the rate of total major adverse limb events in these...
XARELTO®, in combination with aspirin, is indicated to reduce the risk of major cardiovascular events (cardiovascular death, myocardial infarction, and stroke) in adult patients with coronary artery disease (CAD). XARELTO®, in combination with aspirin, is indicated to reduce the risk of major...
TITUSVILLE, NJ,November 14, 2023– The Janssen Pharmaceutical Companies ofJohnson & Johnsontoday announced data from two new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of XARELTO® (ri...
Risk reduction of major cardiovascular events: 2.5 mg twice daily, administered in conjunction with aspirin 75–100 mg once daily.Transitioning from Other Anticoagulant TherapyTransferring to Rivaroxaban from WarfarinDiscontinue warfarin and initiate rivaroxaban as soon as INR <3 in adults and <2.5 in ...
in part because of the expected increased risk in majorbleedingby combiningaspirin, a P2Y12receptor inhibitor, and an anticoagulant. Approvability ofrivaroxabanwas considered largely on the basis of the ATLASACS2–TIMI 51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy...